PRMT5 inhibitor

DRUG CLASS:

PRMT5 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	TNG908 Sensitive: C2 – Inclusion Criteria TNG908 Sensitive : C2	TNG908 Sensitive: C2 – Inclusion Criteria TNG908 Sensitive : C2
MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	TNG462 Sensitive: C2 – Inclusion Criteria TNG462 Sensitive : C2	TNG462 Sensitive: C2 – Inclusion Criteria TNG462 Sensitive : C2
IDH2 mutation	Glioma	IDH2 mutation	Glioma	P-500 Sensitive: C3 – Early Trials P-500 Sensitive : C3	P-500 Sensitive: C3 – Early Trials P-500 Sensitive : C3
IDH1 mutation	Glioma	IDH1 mutation	Glioma	P-500 Sensitive: C3 – Early Trials P-500 Sensitive : C3	P-500 Sensitive: C3 – Early Trials P-500 Sensitive : C3
MTAP deletion	Esophageal Cancer	MTAP deletion	Esophageal Cancer	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3
MTAP deletion	Renal Cell Carcinoma	MTAP deletion	Renal Cell Carcinoma	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3
MTAP deletion	Gallbladder Cancer	MTAP deletion	Gallbladder Cancer	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3
MTAP deletion	Pancreatic Cancer	MTAP deletion	Pancreatic Cancer	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3
MTAP deletion	Ovarian Cancer	MTAP deletion	Ovarian Cancer	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3	AMG 193 Sensitive: C3 – Early Trials AMG 193 Sensitive : C3
TMB-L + ARID1A deletion + CDKN2A deletion + CDKN2B deletion + MTAP deletion + PIK3R1 N564D + NBN P81fs*23	Gallbladder Cancer	TMB-L + ARID1A deletion + CDKN2A deletion + CDKN2B deletion + MTAP deletion + PIK3R1 N564D + NBN P81fs*23	Gallbladder Cancer	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4
NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion	Neurofibrosarcoma	NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion	Neurofibrosarcoma	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4
MTAP deletion + CDKN2A deletion + CDKN2B deletion + BAP1 deletion	Malignant Pleural Mesothelioma	MTAP deletion + CDKN2A deletion + CDKN2B deletion + BAP1 deletion	Malignant Pleural Mesothelioma	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4
EGFR mutation + EGFR amplification + MET amplification + MTAP deletion	Non Small Cell Lung Cancer	EGFR mutation + EGFR amplification + MET amplification + MTAP deletion	Non Small Cell Lung Cancer	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4
CDKN2A deletion + CDKN2B deletion + MTAP deletion + TERT mutation	Melanoma	CDKN2A deletion + CDKN2B deletion + MTAP deletion + TERT mutation	Melanoma	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4
MTAP deletion + PIK3CA mutation	Malignant Pleural Mesothelioma	MTAP deletion + PIK3CA mutation	Malignant Pleural Mesothelioma	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4
PRMT5 overexpression	Retinoblastoma	PRMT5 overexpression	Retinoblastoma	EPZ015666 Sensitive: D – Preclinical EPZ015666 Sensitive : D	EPZ015666 Sensitive: D – Preclinical EPZ015666 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	EPZ015666 Sensitive: D – Preclinical EPZ015666 Sensitive : D	EPZ015666 Sensitive: D – Preclinical EPZ015666 Sensitive : D
MTAP deletion	Colorectal Cancer	MTAP deletion	Colorectal Cancer	MRTX9768 Sensitive: D – Preclinical MRTX9768 Sensitive : D	MRTX9768 Sensitive: D – Preclinical MRTX9768 Sensitive : D
MTAP deletion + KRAS G12C	Lung Adenocarcinoma	MTAP deletion + KRAS G12C	Lung Adenocarcinoma	sotorasib + TNG908 Sensitive: D – Preclinical sotorasib + TNG908 Sensitive : D	sotorasib + TNG908 Sensitive: D – Preclinical sotorasib + TNG908 Sensitive : D
RBM10 mutation	Non Small Cell Lung Cancer	RBM10 mutation	Non Small Cell Lung Cancer	PRT543 Sensitive: D – Preclinical PRT543 Sensitive : D	PRT543 Sensitive: D – Preclinical PRT543 Sensitive : D
U2AF1 S34F	Non Small Cell Lung Cancer	U2AF1 S34F	Non Small Cell Lung Cancer	PRT543 Sensitive: D – Preclinical PRT543 Sensitive : D	PRT543 Sensitive: D – Preclinical PRT543 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib + P-500 Sensitive: D – Preclinical gilteritinib + P-500 Sensitive : D	gilteritinib + P-500 Sensitive: D – Preclinical gilteritinib + P-500 Sensitive : D
MTAP deletion	Solid Tumor	MTAP deletion	Solid Tumor	BMS‐986504 Sensitive: D – Preclinical BMS‐986504 Sensitive : D	BMS‐986504 Sensitive: D – Preclinical BMS‐986504 Sensitive : D
RB1 deletion	Estrogen Receptor Positive Breast Cancer	RB1 deletion	Estrogen Receptor Positive Breast Cancer	GSK3326595 Sensitive: D – Preclinical GSK3326595 Sensitive : D	GSK3326595 Sensitive: D – Preclinical GSK3326595 Sensitive : D
MTAP deletion	Glioblastoma	MTAP deletion	Glioblastoma	TNG908 Sensitive: D – Preclinical TNG908 Sensitive : D	TNG908 Sensitive: D – Preclinical TNG908 Sensitive : D

PRMT5 inhibitor

PRMT5 inhibitor

Associations(25)

Associations
(25)